Viewpoint on the impact of interferon in the treatment of multiple myeloma: Benefit for a small proportion of patients?

Medical Oncology

Volumn 17, Issue 2, 2000, Pages 77-84

  Blade J ^a   Esteve, J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Interferon; Maintenance treatment; Multiple myeloma

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GLUCOCORTICOID; INTERFERON; PREDNISONE;

CELL GROWTH; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG INDUCED DISEASE; GROWTH INHIBITION; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034045288     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02796202     Document Type: Review

References (75)

1. 1 Ludwig CU, Durie BGM, Salmon SE, Moon TE. Tumor growth stimulation in vitro by interferons. Eur J Cancer Clin Oncol 1983; 19: 1625-1632.
2. 2 Brenning G. The in vitro effect of leucocyte alfa-interferon on human myeloma cells in a semisolid agar culture system. Scand J Haematol 1985; 35: 178-185.
3. 3 Schwabe M et al. Disruption by interferon-alpha of an interleukin 6 growth loop in IL-6 dependent U266 myeloma cells by homologous and heterologous downregulation of the IL-6 receptor alpha and beta chains. J Clin Invest 1994; 94: 2317-2325.
4. 4 Einhorn S, Blomgren H, Strander H. Interferon and spontaneous cytotoxicity in man. I. Enhancement of the spontaneous cytotoxicity of peripheral lymphocytes by human leucocyte Interferon. Int J Cancer 1978; 22: 405-412.
5. 5 Herberman RR, Ortaldo JR, Bonnard GD. Augmention by Interferon of human natural antibody-dependent cell-mediated cytotoxicity. Nature 1978; 277: 275-277.
6. 6 Toy JL. The interferons. Clin Exp Immunol 1983; 54: 1-13.
7. 7 Stiehm Er, Kronenberg LH, Rosenblatt HM, Bryson Y, Merigan TC. Interferon: immunobiology and clinical significance. Ann Intern Med 1982; 96: 80-93.
8. 8 Tanaka H et al. Sensitive inhibitory effect of interferon-alpha on M-protein secretion of human myeloma cells. Blood 1989; 74: 1718-1722.
9. 9 McGinnes K., Penny R. Effect of interferon on the in vitro synthesis of paraprotein by plasma cells in myeloma. Acta Haematol 1988; 79: 72-76.
10. 10 Shimizu S et al. Establishment of two interleukin-6 (B-cell stimulatory factor 2/interferon-beta 2) dependent human bone marrow derived myeloma cell lines. J Exp Med 1989; 169: 334-339.
11. 11 Jourdan M et al. IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. J Immunol 1991; 147: 4402-4407.
12. 12 Jelinek D et al. Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression. J Clin Invest 1997; 99: 447-456.
13. 13 Bladé J, López-Guillermo A, Tassies D, Montserrat E, Rozman C. Development of aggressive plasma cell leukemia under interferon-alpha therapy. Br J Haematol 1991; 79: 523-525.
14. 14 Sawamura N et al. Plasma cell leukemia with alpha-interferon therapy in myeloma. Br J Haematol 1992; 82: 631.
15. 15 Portier M et al. Gamma-interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood 1993; 81: 3076-3082.
16. 16 Palumbo A et al. Recombinant interferon-gamma inhibits the in vitro proliferation of human myeloma cells. Br J Haematol 1994; 86: 726-732.
17. 17 Quesada R et al. Recombinant interferon-gamma in hairy cell leukemia, multiple myeloma and Waldenström's macroglobulinemia. Am J Hematol 1988; 29: 1-4.
18. 18 Mellstedt H et al. Interferon therapy in myelomatosis. Lancet 1979; i: 245-247.
19. 19 Ohno R et al. Treatment of multiple myeloma with recombinant human leukocyte A interferon. Cancer Treat Rep 1985; 60: 1433-1435.
20. 20 Quesada JR et al. Treatment of multiple myeloma with recombinant alpha-interferon. Blood 1986; 67: 275-278.
21. 21 Eastern Cooperative Study Group on Monoclonal Gammopathies (ECOG). Low-dose interferon-alpha in stage-1 multiple myeloma and in IgM monoclonal gammopathy. Ann Hematol 1992; 64: 123-127.
22. 22 Ahre A et al. High doses of natural alpha-interferon (alpha-IFN) in the treatment of multiple myeloma. A pilot study from the Myeloma Group of Central Sweden (MGCS). Eur J Haematol 1988; 41: 123-130.
23. 23 Ahre A et al. High doses of natural alpha-interferon (alpha-IFN) in the treatment of multiple myeloma. A pilot study from the Myeloma Group of Central Sweden (MGCS). Eur J Haematol 1988; 41: 123-130.
24. 24 Ludwig H et al. Recombinant interferon-alpha-2c versus polychemotherapy (VCMP) for treatment of multiple myeloma: a prospective randomized trial. Eur J Cancer Clin Oncol 1986; 22: 111-116.
25. 25 Costanzi JJ et al. Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma. J Clin Oncol 1985; 3: 654-659.
26. 26 Ohno R, Kimura K. Treatment of multiple myeloma with recombinant interferon alpha-2a. Cancer 1986; 57: 1685-1688.
27. 27 Wagstaff J, Loynds P, Scarffe JH. Phase II study of rDNA human alpha-2 interferon in multiple myeloma. Cancer Treat Rep 1985; 69: 495-498.
28. 28 Case DC et al. Phase II study of rDNA alpha-2-interferon (Intron A) in patients with multiple myeloma utilizing an escalating induction phase. Cancer Treat Rep 1986; 70: 1251-1254.
29. 29 San Miguel JF et al. Combination of interferon and dexamethasone in refractory multiple myeloma. Hematol Oncol 1990; 8: 185-189.
30. 30 Alexanian R, Barlogie B, Gutterman J. Alpha-interferon combination therapy of resistant myeloma. M J Clin Oncol 1991; 14: 188-192.
31. 31 Gertz M, Kalish LA, Kyle RA. Phase III study comparing vincristine, doxorubicin (adriamycin) and dexmethasone (VAD) chemotherapy with VAD plus recombinant interferon alpha-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1995; 18: 475-481.
32. 32 Cooper MR, Welander CE. Interferons in the treatment of multiple myeloma. Cancer 1987; 59: 594-600.
33. 33 Cooper MR et al. Alpha-2 interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I - II trial. Cancer Treat Rep 1986; 70: 473-476.
34. 34 Oken MM et al. Chemotherapy plus interferon (rIFN) in the treatment of multiple myeloma. Proc Am Soc Clin Oncol 1990; 9: 288.
35. 35 Montuoro A et al. Alpha-2a interferon/Melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma. Br J Haematol 1990; 76: 365-368.
36. 36 Österborg et al. Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Blood 1993; 81: 1428-1434.
37. 37 Oken MM et al. The effect of adding interferon (rINF-alpha2) or high-dose cyclophosphamide to BVMCP to treat multiple myeloma: results from an ECOG phase III trial. Blood 1995; 86 (Suppl. 1): 441a.
38. 38 Cooper MR et al. A randomized trial comparing melphalan/prednisone with or without interferon alpha-2b in newly diagnosed patients with multiple myeloma: a Cancer and Acute Leukemia Group B study. J Clin Oncol 1993; 11: 155-160.
39. 39 Casassus Ph et al. Randomized comparison of interferon-alpha with VCMP/VBAP regimen as the induction phase of untreated multiple myeloma: results of the KIF multicentre trial. Blood 1995; 86 (Suppl. 1): 441a.
40. 40 Capnist G et al. Impact of interferon a induction chemotherapy and maintenance treatment for multiple myeloma. Preliminary results of a multicenter study by the Italian non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG). Acta Oncol 1994; 33: 527-529.
41. 41 Ludwig Het al. Interferon alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol 1995; 6: 467-476.
42. 42 The Nordic Myeloma Study Group. Interferon-alpha-2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma: a Nordic randomized controlled trial; Ann Intern Med 1996; 124: 212-222.
43. 43 Abrahamson GM et al. A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma. Br J Haematol 1996; 94: 659-664.
44. 44 Joshua DE et al. Australian Leukemia Study Group Myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma. Br J Haematol 1997; 97: 38-45.
45. 45 Dimopoulos MA, Weber D, Delasalle KB, Alexanian R. Combintion therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma. Cancer 1993; 72: 2589-2592.
46. 46 Wheatley K (on behalf of the Myeloma Trialists' Collaborative Group). Which myeloma patients benefit from interferon therapy? An overview of 24 randomized trials with 4000 patients. Br J Haematol 1998; 102: 140.
47. 47 Durie BGM, Rusell DH, Salmon SE. Reappraisal of plateau phase in multiple myeloma. Lancet 1980; 2: 65-67.
48. 48 Belch A et al. A randomized trial of maintenance versus no maintenance with melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988; 57: 94-99.
49. 49 Bergsagel DE et al. The chemotherapy of plasma cell myeloma and the incidence of acute leukemia. N Engl J Med 1979; 301: 743-748.
50. 50 Joshua DE, Brown RD, Gibson J. Multiple myeloma: why does the disease escape from plateau phase? Br J Haematol 1994; 89: 667-671.
51. 51 Bladé J, Kyle RA. Monoclonal gammopathies of undetermined significance. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC (eds) Myeloma. Biology and Management. Second edn. Oxford University Press: Oxford 1998; pp 513-544.
52. 52 Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med 1980; 302: 1347-1349.
53. 53 Kyle RA. Monoclonal gammopathy of undetermined significance and solitary plasmacytoma: implications for progression to overt myeloma. Hemaltol Oncol Clin North Am 1997; 11: 71-78.
54. 54 Peest D et al. Cytokine therapy in multiple myeloma. Br J Haematol 1996; 94: 425-432.
55. 55 Mandelli F et al. Maintenance treatment with recombinant interferon alpha-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990; 322: 1430-1434.
56. 56 Westin J et al. Interferon alpha-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Br J Haematol 1995; 89: 561-568.
57. 57 Browman GP et al. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1995; 13: 2354-2360.
58. 58 Bladé J et al. Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from the Spanish Cooperative Group PETHEMA. Leukemia 1998; 12: 1144-1148.
59. 59 Salmon SE et al. Combination chemotherapy, glucocorticoids, and interferon alpha in the treatment of multiple myeloma: a Southwest Oncolocy Group study. J Clin Oncol 1994; 12: 2405-2414.
60. 60 Peest D et al. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma: a prospective trial of the German Myeloma Treatment Group. Eur J Cancer 1995; 31A: 146-151.
61. 61 Drayson MT, Chapman CE, Dunn JA, Olujohungbe AB, MacLennan ICM. MRC trial of alpha-2 interferon maintenance therapy in first plateau phase of multiple myeloma. Br J Haematol 1998; 101: 195-202.
62. 62 Grosbois B et al. Interferon maintenance therapy in multiple myeloma patients achieving plateau phase after induction therapy: multicenter randomized trial. Blood 1997; 90 (Suppl. 1): 356a.
63. 63 Offidani M et al. Two dosage interferon-alpha-2b maintenance therapy in patients affected by low-risk multiple myeloma in plateau phase: a randomized trial. Haematologica 1998; 83: 40-47.
64. 64 Cunningham D et al. A randomized trial of maintenance therapy with Intron A following high-dose melphalan and ABMT in myeloma. Proc Am Soc Clin Oncol 1993; 12: 364.
65. 65 Cunningham D et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998; 102: 495-502.
66. 66 Björkstrand B et al. 2522 autotransplants in multiple myeloma. A registry study from the European group for blood and marrow transplantation (EBMT). Blood 1997; 90 (Suppl. 1): 419a.
67. 67 Alegre A et al. Autologous peripheral blood stemcell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Bone Marrow Transplant 1998; 21: 133-140.
68. 68 Harouseau JL et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood 1995; 85: 3077-3085.
69. 69 Palumbo A et al. Multiple myeloma: Intensified maintenance therapy with recombinant interferon-alpha-2b plus glucocorticoids. Eur J Haematol 1992; 49: 93-97.
70. 70 Boccardoro M et al. Melphalan and prednisone (MP) followed by interferon plus dexamethasone maintenance therapy improves remission duration of myeloma patients. Blood 1997; 90 (Suppl. 1): 355a.
71. 71 Salmon SE et al. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1998; 16: 890-896.
72. 72 Berenson J, Crowley J, Barlogie B, Salmon S. Alternate day oral prednisone maintenance therapy improves progression-free survival and overall survival in multiple myeloma patients. Blood 1998; 92 (Suppl. 1): 318a.
73. 73 Wisloff F, Hjorth M, Kaasa S, Westin J. Effect of interferon on the health-related quality of life of multiple myeloma: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. Br J Haematol 1996; 94: 324-332.
74. 74 Ludwig H, Fritz E, Neuda J, Durie BGM. Patient preferences for interferon alpha in multiple myeloma. J Clin Oncol 1997; 15: 1672-1679.
75. 75 Pulsoni A et al. The Italian experience on interferon as maintenance treatment in multiple myeloma: ten years after. Blood 1998; 92: 2184-2186.